ENTYVIOCONNECT BRIDGE Trademark

Trademark Overview

On Wednesday, April 25, 2018, a trademark application was filed for ENTYVIOCONNECT BRIDGE with the United States Patent and Trademark Office. The USPTO has given the ENTYVIOCONNECT BRIDGE trademark a serial number of 87892530. The federal status of this trademark filing is REGISTERED as of Tuesday, August 27, 2019. This trademark is owned by Millennium Pharmaceuticals, Inc.. The ENTYVIOCONNECT BRIDGE trademark is filed in the Insurance & Financial Services category with the following description:

Providing a health care patient access program to provide drugs free of charge on a continuing basis to eligible patients experiencing a sudden loss or gap in their commercial coverage, namely, financial administration of medication reimbursement programs and services
entyvioconnect bridge

General Information

Serial Number87892530
Word MarkENTYVIOCONNECT BRIDGE
Filing DateWednesday, April 25, 2018
Status700 - REGISTERED
Status DateTuesday, August 27, 2019
Registration Number5846457
Registration DateTuesday, August 27, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 8, 2019

Trademark Statements

Goods and ServicesProviding a health care patient access program to provide drugs free of charge on a continuing basis to eligible patients experiencing a sudden loss or gap in their commercial coverage, namely, financial administration of medication reimbursement programs and services

Classification Information

International Class036 - Insurance; financial affairs; monetary affairs; real estate affairs.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateWednesday, November 28, 2018
Primary Code036
First Use Anywhere DateMonday, July 23, 2018
First Use In Commerce DateMonday, July 23, 2018

Trademark Owner History

Party NameMillennium Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCambridge, DE 02139
Party NameMillennium Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, DE 02139
Party NameMillennium Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, DE 02139

Trademark Events

Event DateEvent Description
Tuesday, May 29, 2018PRIORITY ACTION E-MAILED
Saturday, April 28, 2018NEW APPLICATION ENTERED
Friday, May 4, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 22, 2018ASSIGNED TO EXAMINER
Tuesday, May 29, 2018PRIORITY ACTION WRITTEN
Tuesday, May 29, 2018NOTIFICATION OF PRIORITY ACTION E-MAILED
Tuesday, January 8, 2019PUBLISHED FOR OPPOSITION
Friday, June 22, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, November 13, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, November 21, 2018ASSIGNED TO LIE
Wednesday, November 28, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 28, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 29, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 30, 2018LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, December 19, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 8, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, June 26, 2019TEAS STATEMENT OF USE RECEIVED
Thursday, July 18, 2019STATEMENT OF USE PROCESSING COMPLETE
Tuesday, March 5, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, June 26, 2019USE AMENDMENT FILED
Thursday, July 18, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, July 24, 2019ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, July 25, 2019NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, August 27, 2019REGISTERED-PRINCIPAL REGISTER
Thursday, August 29, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 27, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, September 23, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, September 23, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

Related Keywords

bridge entyvioconnect commercial coverage their loss sudden namely financial programs services reimbursement